文献速递骨质疏松与代谢性骨病创伤骨科

他汀类药物治疗骨质疏松症疗效的系统评价与Meta分析

Efficacy of statins for osteoporosis: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2016-11-25

本研究通过汇总33项临床试验(含23项观察性研究和10项随机对照试验)评估他汀类药物对骨折风险、骨密度及骨代谢标志物的影响。结果显示他汀治疗与降低整体骨折和髋部骨折风险、升高全髋和腰椎骨密度及骨钙素相关,且对男性骨质疏松患者似乎更有效。

要点

  • 他汀治疗与整体骨折风险降低相关(OR=0.81,95%CI 0.73-0.89)。
  • 他汀治疗与髋部骨折风险降低相关(OR=0.75,95%CI 0.60-0.92)。
  • 他汀对男性患者似乎比女性患者更有效,女性亚组效果轻微或无统计学意义。

核心结论

  • 他汀治疗可能与整体骨折和髋部骨折风险降低、全髋及腰椎骨密度升高和骨钙素改善相关。
  • 他汀治疗对男性患者的效果可能大于女性患者。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase和Cochrane Library数据库从建库至2016年5月的临床试验。
  • 共纳入33项研究,包括23项观察性研究(16项队列研究和7项病例对照研究)和10项随机对照试验。
  • 他汀组314,473例患者,对照组1,349,192例患者。
  • 按骨骼部位、患者性别和随访时长进行亚组分析。

主要发现

  • 他汀降低整体骨折风险(OR=0.81,95%CI 0.73-0.89)和髋部骨折风险(OR=0.75,95%CI 0.60-0.92)。
  • 他汀与全髋骨密度升高相关(SMD=0.18,95%CI 0.00-0.36),与腰椎骨密度升高相关(SMD=0.20,95%CI 0.07-0.32)。
  • 他汀与骨形成标志物骨钙素改善相关(SMD=0.21,95%CI 0.00-0.42)。
  • 对椎体骨折、上肢骨折、股骨颈骨密度、骨特异性碱性磷酸酶(BALP)和血清I型胶原C端肽(S-CTX)无正向效应。
  • 与男性亚组相比,女性亚组的效果仅轻微正向或无统计学意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our meta-analysis assessed the efficacy of statins on the risk of fracture, bone mineral density (BMD), and the markers of bone metabolism by collecting data from 33 clinical trials. We found that statin treatment was associated with bone metabolism. And statins seemed to be more effective on male patients with osteoporosis. The efficacy of statins for the treatment of osteoporosis has been controversial in previous studies and meta-analyses. Our meta-analysis was conducted to examine in detail the efficacy of statins on osteoporosis. We searched PubMed, Embase, and the Cochrane Library databases for clinical trials from inception to May 2016. We included studies that described the effect of statins on the risk of fracture, BMD, or bone turnover markers. Moreover, we also conducted subgroup analyses according to the skeleton site, patient gender, and length of follow-up. A total of 33 studies which included 23 observational studies (16 cohort studies and 7 case-control studies) and 10 randomized controlled trials (RCTs) were evaluated. These 33 studies included 314,473 patients in statin group and 1,349,192 patients in control group. Statins decreased the risk of overall fractures (OR = 0.81, 95% CI 0.73-0.89) and hip fractures (OR = 0.75, 95% CI 0.60-0.92). Furthermore, the use of statins was associated with increased BMD at the total hip (standardized mean difference (SMD) = 0.18, 95% CI 0.00-0.36) and lumbar spine (SMD = 0.20, 95% CI 0.07-0.32) and improved the bone formation marker, osteocalcin (OC) (SMD = 0.21, 95% CI 0.00-0.42). However, there was no positive effect on vertebral fractures, upper extremity fractures, BMD at the femoral neck, bone-specific alkaline phosphatase (BALP), and serum C-terminal peptide of type I collagen (S-CTX). Also, compared with male subgroups, the effect on female subgroups was only slightly positive or of no statistical significance. Our meta-analysis indicates that statin treatment may be associated with a decreased risk of overall fractures and hip fractures, an increased BMD at the total hip, BMD at the lumbar spine, and OC. Moreover, our results also show that statin treatment may have a greater effect on male patients than on female patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. An T, Hao J, Sun S, et al. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2016. PMID: 27888285. doi:10.1007/s00198-016-3844-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。